Standardizing *Plasmodium falciparum* infection prevalence measured via microscopy versus rapid diagnostic test

Bonnie Mappin, Ewan Cameron, Ursula Dalrymple, Daniel J. Weiss, Donal Bisanzio, Samir Bhatt and Peter W. Gething*

**Abstract**

**Background:** Large-scale mapping of *Plasmodium falciparum* infection prevalence relies on opportunistic assemblies of infection prevalence data arising from thousands of *P. falciparum* parasite rate (PfPR) surveys conducted worldwide. Variance in these data is driven by both signal, the true underlying pattern of infection prevalence, and a range of factors contributing to ‘noise’, including sampling error, differing age ranges of subjects and differing parasite detection methods. Whilst the former two noise components have been addressed in previous studies, the effect of different diagnostic methods used to determine PfPR in different studies has not. In particular, the majority of PfPR data are based on positivity rates determined by either microscopy or rapid diagnostic test (RDT), yet these approaches are not equivalent; therefore a method is needed for standardizing RDT and microscopy-based prevalence estimates prior to use in mapping.

**Methods:** Twenty-five recent Demographic and Health surveys (DHS) datasets from sub-Saharan Africa provide child diagnostic test results derived using both RDT and microscopy for each individual. These prevalence estimates were aggregated across level one administrative zones and a Bayesian probit regression model fit to the microscopy-versus RDT-derived prevalence relationship. An errors-in-variables approach was employed to account for sampling error in both the dependent and independent variables. In addition to the diagnostic outcome, RDT type, fever status and recent anti-malarial treatment were extracted from the datasets in order to analyse their effect on observed malaria prevalence.

**Results:** A strong non-linear relationship between the microscopy and RDT-derived prevalence was found. The results of regressions stratified by the additional diagnostic variables (RDT type, fever status and recent anti-malarial treatment) indicate that there is a distinct and consistent difference in the relationship when the data are stratified by febrile status and RDT brand.

**Conclusions:** The relationships defined in this research can be applied to RDT-derived PfPR data to effectively convert them to an estimate of the parasite prevalence expected using microscopy (or vice versa), thereby standardizing the dataset and improving the signal-to-noise ratio. Additionally, the results provide insight on the importance of RDT brands, febrile status and recent anti-malarial treatment for explaining inconsistencies between observed prevalence derived from different diagnostics.

**Keywords:** Malaria, *Plasmodium falciparum*, Africa, RDT, Microscopy, Diagnostics

*Correspondence: peter.gething@zoo.ox.ac.uk

Spatial Ecology and Epidemiology Group, Department of Zoology, University of Oxford, Tinbergen Building, Oxford OX1 3PS, UK

© 2015 Mappin et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

Large-scale maps of *Plasmodium falciparum* infection prevalence [1–3] are increasingly used to inform disease control planning, implementation and evaluation at national to global scales [4], and as a basis for disease burden estimation and the monitoring of progress towards international targets [4–7]. Mapping at the continental or global scale relies on opportunistic assemblies of data on infection prevalence arising from thousands of *P. falciparum* parasite rate ( PfPR ) surveys conducted in different countries. The between-site variance observed in these *PfPR* estimates arises from both an underlying signal component: the variation of the true infection prevalence and the residual noise component, attributable, not only to the inherent random error, but also to a range of confounding factors that reduce the comparability of *PfPR* measurements from different surveys, most notably, immunological differences in the age ranges of subjects surveyed [8] and differences in parasite detection methods. Whilst random error and age-standardization have been addressed in previous mapping efforts, the effect of different diagnostic methods has not. Previous research has defined the functional relationship between microscopy and polymerase chain reaction (PCR) detection [9], but little research has explored the functional differences between microscopy and rapid diagnostic test (RDT). Given that the majority of *PfPR* data are based on positivity rates measured by either microscopy or RDT, and that the sensitivity and specificity of these approaches are not identical [10], it is crucial to understand the functional differences between these two approaches.

Detection of parasite infection via microscopy has formed the mainstay of modern *PfPR* surveys for many decades [11]. Giemsa-stained thick smear microscopy under ideal conditions where stains are prepared correctly and the slide is analysed by an expert is highly accurate for infection diagnosis at densities above 100 parasites per µL [12]. Since the early 2000s, however, economically preferable RDTs have become widely used in field locations as they allow quick diagnosis through antigen-detection without the need for laboratory equipment. Figure 1 illustrates the increasing role of RDT measurements in the global assembly of *PfPR* surveys maintained by the Malaria Atlas Project (MAP). This increase is mirrored in clinical settings, where the introduction of RDTs has enabled improvements in the proportion of suspected malaria cases receiving parasitological diagnosis (e.g., rising from 20 to 62% between 2006 and 2013 in the African public sector and with over half of reported cases in 2013 identified by RDTs [4]).

World Health Organization (WHO) guidelines state that all RDTs used for malaria diagnosis pass the following criteria in the WHO Malaria RDT product testing programme: have a panel detection score of at least 75% at 200 parasites per µL, with a false positive rate <10 and <5% of tests deemed invalid [13]. RDTs used in *PfPR* surveys undergo extensive testing as part of WHO quality assurance procedures [14]. However, despite these procedures, the relative performance of RDTs versus microscopy in the field is influenced by a wide range of factors that cannot be fully captured in standardized quality assurance tests. RDTs have been shown to become ineffective through poor storage [15], and can display false positivity due to the perseverence of antigens detected in the blood after both anti-malarial treatment and parasite clearance [16, 17]. Despite these limitations, no simple

![Fig. 1](image-url)
adjustment factors currently exist to functionally map between RDT-derived PfPR measurements and those likely to be observed using microscopy.

To address the need for cross-comparability of microscopy- and RDT-derived PfPR measurements, a large database of individual-level parasitological outcomes tested, using both methods, was assembled from national household surveys conducted in sub-Saharan Africa. A hierarchical Bayesian model was then developed to capture the functional divergence in PfPR measured using the two techniques. The extent of this divergence was further explored in sub-analyses stratified using the presence or absence of symptomatic infection (i.e., fever), recent treatment with effective anti-malarial drugs and the type and brand of RDT used.

Methods
Data collection
The Demographic and Health Surveys (DHS) Programme collects nationally representative health and socio-economic information from over 90 countries worldwide through cross-sectional household surveys [18]. Typically, malaria testing within DHS Programme is limited to children under five years old. For this study, children from sub-Saharan African DHS datasets, whose malaria diagnostic outcome was recorded using both microscopy and RDT, were selected. Table 1 lists the 25 DHS Programmes that met these inclusion criteria as of 15 July, 2015, which were tabulated from 118,078 individuals tested for falciparum malaria. The administrative zone (ADMIN1) of residence and the RDT and microscopy diagnostic outcome was recorded for each individual. Where available, the following additional factors were extracted: (1) RDT brand; (2) RDT type used whether the RDT detected histidine-rich protein 2 (HRP2) or HRP2 and Plasmodium lactate dehydrogenase (pLDH) or HRP2 and Plasmodium vivax-specific pLDH; (3) whether the individual had been febrile within the last two weeks; and (4) whether febrile individuals had received treatment with artemisinin-based combination therapy (ACT) anti-malarial within the previous 2 weeks.

Modelling the relationship between microscopy- and RDT-derived PfPR
Individual-level data on infection status were aggregated within ADMIN1 zones across sub-Saharan Africa, and microscopy-derived (PfPR\textsuperscript{MIC}) and RDT-derived (PfPR\textsuperscript{RDT}) infection prevalence were calculated for each zone. Any estimates from <10 individuals were excluded. A Bayesian probit regression was fit to the resulting 458 pairwise PfPR observations with an errors-in-variables approach [19]. This approach was employed to account for sampling error in both the RDT-derived measurement and the microscopy-derived measurement. In hierarchical Bayesian notation,

\begin{align*}
    n_i^{\text{MIC}} & \sim \text{Binom}(p_i^{\text{MIC}}, n_i^{\text{tot}}) \quad (1) \\
    n_i^{\text{RDT}} & \sim \text{Binom}(p_i^{\text{RDT}}, n_i^{\text{tot}}) \quad (2) \\
    \phi^{-1}(p_i^{\text{MIC}}) & = \alpha + \beta \times \phi^{-1}(p_i^{\text{RDT}}) \quad (3) \\
    \phi^{-1}(p_i^{\text{RDT}}) & \sim \text{Norm}(\mu_i, \sigma_i) \quad (4) \\
    \{\mu_i, \sigma_i\}(i = 1, \ldots, n^{\text{obs}}) & \sim F \quad (5) \\
    F & \sim DP(G_\phi, m) \quad (6) \\
    \alpha, \beta, \Theta, m & \sim \pi, \quad (7)
\end{align*}

where $n_i^{\text{MIC}}$ and $n_i^{\text{RDT}}$ are the number of microscopy and RDT positive counts, respectively, with $n_i^{\text{tot}}$ the total number of individuals tested in each of the $i = 1 \ldots, n^{\text{obs}}$ site-specific aggregations; likewise, $p_i^{\text{MIC}}$ and $p_i^{\text{RDT}}$ are the long-run PfPR\textsuperscript{MIC} and PfPR\textsuperscript{RDT}; $\phi^{-1}(\cdot)$ denotes the inverse probit function that maps the linear predictor within the range of valid probabilities (zero to one); $\alpha$ and $\beta$ are the unknown parameters of the regression model; $\mu_i$ and $\sigma_i$ are the mean and standard deviation of the Normal mixture component from which the $i$-th $\phi^{-1}(p_i^{\text{RDT}})$ is drawn; each $\mu_i$ and $\sigma_i$ pair is drawn from a single realisation, $F$, of the Dirichlet process, $DP(G_\phi, m)$, with reference density, $G_\phi$, (here a single Normal controlled by the hyper-parameters, $\Theta$) and concentration index $m$; while $\pi$ represents a family of priors and hyperpriors chosen for conjugacy with the upper layers.

The use of Bayesian inference with an errors-in-variables structure requires the specification of a prior for the baseline distribution of long-run RDT-derived prevalence, which in the above is handled by the highly flexible semi-parametric form known as the Dirichlet process mixture model [20]. To facilitate posterior simulation via Gibbs sampling for ordinary probit regressions, Albert and Chib [21] propose an augmented variable method based on the introduction of an additional unit-variance, Normal latent variable per binary response, i.e., a non-observed or inferred variable. Here this approach is extended to the errors-in-variables context with a further latent variable for each binary observation in the RDT-derived measurement and couple the procedure to a Polya urn sampler for the Dirichlet process (from the DPPackage library in R [22]). Leave-one-out cross-validation was employed to evaluate the statistical performance of the fitted model to predict the microscopy-derived prevalence from the RDT-derived prevalence.
Table 1  Surveys included in analysis, the number of individuals included within each survey, the RDT type, the RDT brand, the RDT model if known, and the age range of patients screened for parasitaemia within each survey.

| Country                        | Survey year | Type of survey | No of individuals | No of ADMIN1 | RDT type     | RDT brand | RDT model | Age range of individuals |
|-------------------------------|-------------|----------------|-------------------|--------------|--------------|-----------|-----------|-------------------------|
| Angola                        | 2011        | MIS            | 3322              | 21           | HRP2/Pv-pLDH | SD Bioline | 05FK80    | 6–59 months             |
| Benin                         | 2011–2012   | Standard DHS   | 3736              | 12           | HRP2         | Paracheck  | 3030100   | 1–59 months             |
| Burkina Faso                  | 2010        | Standard DHS   | 5741              | 13           | HRP2         | Paracheck  | 3030100   | 6–59 months             |
| Burundi                       | 2012        | MIS            | 3718              | 18           | HRP2/pan-pLDH| SD Bioline | 05FK60    | 6–59 months             |
| Cote d’Ivoire                 | 2011–2012   | Standard DHS   | 3927              | 14           | HRP2         | SD Bioline | 05FK50    | 6–74 months             |
| Democratic Republic of Congo  | 2013–2014   | Standard DHS   | 8135              | 26           | HRP2         | SD Bioline | 05FK50    | 6–59 months             |
| The Gambia                    | 2013        | Standard DHS   | 3262              | 8            | HRP2/pan-pLDH| SD Bioline | Unknown   | 6–59 months             |
| Guinea                        | 2012        | Standard DHS   | 3198              | 8            | HRP2/pan-pLDH| First Response I16FRC30 | 6–59 months             |
| Liberia                       | 2009        | MIS            | 4960              | 18           | HRP2         | Paracheck  | Unknown   | 6 months–6 years       |
| Liberia                       | 2011        | MIS            | 3060              | 18           | HRP2         | First Response I13FRC30 | 6–59 months             |
| Madagascar                    | 2011        | MIS            | 6821              | 23           | HRP2/pan-pLDH| CareStart  | Unknown   | 6–64 months             |
| Madagascar                    | 2013        | MIS            | 6147              | 22           | HRP2/pan-pLDH| CareStart  | Unknown   | 6–65 months             |
| Malawi                        | 2012        | MIS            | 2105              | 3            | HRP2         | SD Bioline | 05FK50    | 6–59 months             |
| Mali                          | 2010        | Special EA&P   | 1716              | 9            | HRP2         | Paracheck  | Unknown   | 6–59 months             |
| Mali                          | 2012–2013   | Standard DHS   | 5640              | 6            | HRP2         | Paracheck  | 3030100   | 0–83 months             |
| Mozambique                    | 2011        | Standard DHS   | 4891              | 13           | HRP2/pan-pLDH| SD Bioline | 05FK80    | 6–59 months             |
| Nigeria                       | 2010        | MIS            | 5127              | 38           | HRP2         | Paracheck  | 3030100   | 6–59 months             |
| Rwanda                        | 2010        | Standard DHS   | 4887              | 5            | HRP2         | First Response I13FRC30 | 6–73 months             |
| Senegal                       | 2008–2009   | MIS            | 3947              | 15           | HRP2         | Paracheck  | 3030100   | 6–59 months             |
| Senegal                       | 2010–2011   | Standard DHS   | 4603              | 14           | HRP2         | Paracheck  | 3030100   | 6–77 months             |
| Senegal                       | 2012–2013   | Continuous DHS | 7252              | 14           | HRP2/pan-pLDH| SD Bioline | 05FK60    | 6–76 months             |
| Senegal                       | 2014        | Continuous DHS | 6760              | 14           | HRP2/pan-pLDH| SD Bioline | Unknown   | 6–59 months             |
| Tanzania                      | 2011–2012   | Standard AS    | 7264              | 30           | HRP2/pan-pLDH| SD Bioline | 05FK60    | 6–59 months             |
| Togo                          | 2013–2014   | Standard DHS   | 3861              | 6            | HRP2/pan-pLDH| First Response | Unknown   | 6–59 months             |
| Uganda                        | 2009        | MIS            | 3998              | 95           | HRP2         | Paracheck  | 3030100   | 0 month–5 years         |

MIS  Malaria Indicator Survey, DHS Demographic Health Survey, EA&P anaemia and malaria parasitaemia survey

Analysis of factors influencing the relationship between PPR\text{MIC} and PPR\text{RDT}

To explore possible factors driving residual noise in the relationship between microscopy and RDT-derived prevalence, the Bayesian regression analysis described above was repeated on various stratified sub-sets of the data: by fever status, treatment status, RDT type, and RDT brand (see Fig. 2 for more details). For each factor pre- and post-stratification akaike information criterion (AIC) scores [23] were compared to determine whether the stratification substantially improved the net information content of the fitted regression model.

Results

Modelled PPR\text{MIC} versus PPR\text{RDT} relationship

Figure 3a shows the aggregated prevalence data points and their associated uncertainties, the (point-wise) median and 95 % credible interval curves from the posterior of the probit regression model, as well as the line of equality for reference. A systematic tendency for PPR\text{RDT} to exceed PPR\text{MIC} when measured in the same population was observed, indicating that RDTs tend to give more false positives than false negatives, i.e., most (71.6 %) points in Fig. 3a lie below line of equality. The best-fit regression function relating PPR\text{RDT} to PPR\text{MIC} was:

$$\phi^{-1}(p_i^{\text{MIC}}) = -0.22 + 0.97 \times \phi^{-1}(p_i^{\text{RDT}})$$

(8)

The results from the leave-one-out cross-validation procedure applied to this model are shown in Fig. 3b. The correlation coefficient between the observed and predicted PPR\text{MIC} was 0.921, the mean square error was 0.84 %, and the mean absolute error was 5.77 % indicating a well-performing model with strong predictive capacity.
Analysis of factors influencing the relationship between \( PfPR_{MIC} \) and \( PfPR_{RDT} \)

Figure 4a shows the data stratified by individual fever status and the resulting fitted curves. The prevalence rate estimated by RDT amongst non-febrile children is more closely aligned with the prevalence estimated by microscopy than amongst febrile children. The difference in AIC scores between the original (non-stratified) model and that stratified by fever status confirms that the stratified model performs substantially better (see Table 2).

Recent treatment with ACT has a marked effect on the observed relationship between microscopy and RDT-derived prevalence as seen in Fig. 4b, greatly increasing \( PfPR_{RDT} \) relative to \( PfPR_{MIC} \). The ‘taken an ACT’ sub-set relationship is less precisely determined (note the larger spread and larger confidence intervals in Fig. 4b). In addition to the smaller sample size, this likely reflects the irregular occurrence of false positivity due to perseverance of antigens after anti-malarial treatment and parasite clearance [16, 17]. Although the stratified model is preferred for its lower AIC score (see Table 2), the unpredictability of the false positivity among the taken-ACT children indicates that RDT diagnosis is not ideal and that microscopy would provide a more conclusive diagnosis.

In contrast, there is far less divergence between the prevalence rates estimated by RDTs detecting HRP2 alone compared with HRP2 and pan-pLDH, or HRP2 and \( P.\) vivax-pLDH, as seen in Fig. 4c, and indeed the stratified model in this case is not favoured by the AIC score. Therefore, there is no benefit in stratifying by RDT type.

Figure 4d shows the relationship of the \( PfPR_{MIC} \) and \( PfPR_{RDT} \) by RDT brand. The CareStart (HRP2/pan-pLDH) has a near one–one relationship (parameter values being estimated near to \( \alpha \) equal 0 and \( \beta \) equal 1) whereas First Response (HRP2) and SD Bioline (HRP2) diverge to \( PfPR_{RDT} \), being almost double \( PfPR_{MIC} \) at \( PfPR_{RDT} \) at 40 %. The AIC score of the RDT brand

Fig. 2 The stratified sub-sets of the data based on fever status, ACT usage, RDT type, and RDT brand
stratified model is significantly lower than the non-stratified model, favouring stratification.

The combination of febrile status and RDT brand was additionally explored. The AIC score of the febrile status with RDT brand stratified model was lower than the non-stratified model, indicating the stratified model to be preferred (see Table 2). The combination of ACT usage and RDT brands was not possible to explore with our dataset due to low sample sizes for the children taken an ACT by RDT brand.

In summary, the AIC scores are lower for the models stratified by febrile status, ACT usage among febrile individuals, RDT brands and febrile status with RDT brands than the non-stratified model, and are thus considered the preferred models. When applying the conversion formula to an RDT-derived prevalence, cross-sectional population, survey dataset, if the population has a known febrile status, known ACT usage among febrile individuals, or RDT brand used is known, the preferred method for estimating the equivalent microscopy prevalence would, therefore, be applying the model specific to that population. The resulting regression function parameters with 95% credible intervals for each of the data sub-sets are listed in Table 3.

Discussion

The models developed in this paper provide a means of converting RDT-derived PfPR measurements into estimates compatible with microscopy-derived PfPR or vice versa. As such, the approach provides an indispensable tool for data standardization, designed to decrease the overall uncertainty associated with models that utilize PfPR data derived using differing diagnostic techniques. This research also illustrates the utility of ancillary factors when converting PfPR metrics to reduce the residual noise. Those wishing to apply the conversions developed here can do so using the coefficients in Table 3.

The models were derived using a hierarchical Bayesian framework implementing an errors-in-variables probit regression with a highly flexible, semi-parametric prior (the Dirichlet process mixture model) for marginalizing over uncertainty in the distribution of RDT-derived prevalence. The statistical reliability and predictive performance of this model has been demonstrated through leave-one-out cross-validation.

The field setting of the joint microscopy and RDT prevalence measurements in the DHS dataset distinguishes the present analysis from previous formal verification studies for RDT accuracy [14]; thus the results presented offer a complementary picture of RDT performance outside of control conditions, but require care in their interpretation. For instance, while one may be confident in supposing that the observed strength of recent treatment with ACT as a factor for overdiagnosis by RDT surveillance is likely due to the known lag between asexual parasite clearance and the antigenic-response targeted by RDTs [24], the apparent role of febrile status in RDT overdiagnosis is less easily explained. Previous studies have also observed higher RDT false positives among febrile patients [25, 26]. Uncovering the causal relationship will be important for the accuracy of analyses forecasting likely cost-benefit analyses of different designs for...
Fig. 4 The fitted regression functions with the 95% credible intervals overlaid on the paired microscopy and RDT derived prevalence data points with their individual error-bounds, for the following stratifications: a febrile (dark blue) and non-febrile children (green), b febrile children who have taken an ACT in the last 2 weeks (purple) and febrile children who have not taken an ACT in the last 2 weeks (red), c RDT detected HRP2 (red), RDT detected HRP2 and pan-pLDH (dark blue) and RDT detected HRP2 and P. vivax-pLDH (yellow), d RDT brand CareStart detected HRP2 (yellow), RDT brand First Response detected HRP2 and pan-pLDH (dark blue), RDT brand First Response detected HRP2 (green), RDT brand Paracheck detected HRP2 (red), RDT brand SD Bioline detected HRP2 and pan-pLDH (purple), RDT brand SD Bioline detected HRP2 and P. vivax-pLDH (dark grey) and RDT brand SD Bioline detected HRP2 (dark green). The line of equality is included in each plot for reference.

Table 2 The estimated AIC for each of the models

| Model                                      | AIC of stratified model | AIC model not stratified | Preferred model |
|--------------------------------------------|-------------------------|--------------------------|-----------------|
| Febrile/non-febrile (stratified model 1)   | 8523.86                 | 8756.76                  | Stratified model|
| Taken ACT/not taken ACT (stratified model 2)| 3700.14                 | 3787.54                  | Stratified model|
| RDT type (stratified model 3)              | 6480.68                 | 6299.77                  | Not stratified  |
| RDT brands (stratified model 4)            | 5970.06                 | 6299.77                  | Stratified model|
| Febrile/non-febrile with RDT brands        | 8023.65                 | 8756.76                  | Stratified model|
Table 3 The estimated parameters for the fitted regression function (Eq. 3) and their 95% credible intervals

| Dataset                                      | $\alpha$  | $\beta$  |
|---------------------------------------------|-----------|----------|
| Overall                                     | $-0.22$ ($-0.24$, $-0.21$) | $0.97$ ($0.95$, $0.99$) |
| Febrile                                     | $-0.37$ ($-0.39$, $-0.34$) | $0.93$ ($0.89$, $0.97$) |
| Non-febrile                                 | $-0.15$ ($-0.17$, $-0.13$) | $0.99$ ($0.96$, $1.01$) |
| Taken an ACT                                | $-0.65$ ($-0.72$, $-0.59$) | $0.71$ ($0.59$, $0.83$) |
| Not taken an ACT                            | $-0.31$ ($-0.34$, $-0.27$) | $0.96$ ($0.91$, $1.00$) |
| HPR2                                        | $-0.25$ ($-0.27$, $-0.24$) | $0.95$ ($0.92$, $0.97$) |
| HPR2/pan-pLDH                               | $-0.08$ ($-0.13$, $-0.04$) | $1.07$ ($1.03$, $1.11$) |
| CareStart (HPR2/pan-pLDH)                   | $-0.16$ ($-0.22$, $-0.10$) | $0.96$ ($0.88$, $1.03$) |
| First Response (HPR2/pan-pLDH)              | $-0.01$ ($-0.15$, $0.13$) | $1.12$ ($1.01$, $1.23$) |
| First Response (HPR2)                       | $-0.03$ ($-0.08$, $0.01$) | $0.92$ ($0.83$, $1.02$) |
| Paracheck (HPR2)                            | $-0.52$ ($-0.58$, $-0.46$) | $0.86$ ($0.81$, $0.93$) |
| SD Bioline (HPR2/pan-pLDH)                  | $-0.15$ ($-0.16$, $-0.13$) | $0.91$ ($0.88$, $0.94$) |
| SD Bioline (HPR2/Pv-pLDH)                   | $-0.31$ ($-0.38$, $-0.24$) | $0.94$ ($0.88$, $0.99$) |
| SD Bioline (HPR2)                           | $-0.16$ ($-0.22$, $-0.10$) | $0.95$ ($0.87$, $1.03$) |
| SD Bioline (HPR2)                           | $-0.53$ ($-0.56$, $-0.49$) | $0.72$ ($0.65$, $0.79$) |
| Febrile with CareStart (HPR2/pan-pLDH)      | $-0.31$ ($-0.54$, $0.02$) | $1.10$ ($0.77$, $1.34$) |
| Febrile with First Response (HPR2/pan-pLDH) | $-0.16$ ($-0.25$, $-0.07$) | $0.90$ ($0.71$, $1.12$) |
| Febrile with First Response (HPR2)          | $-0.58$ ($-0.66$, $-0.50$) | $0.84$ ($0.70$, $0.98$) |
| Febrile with Paracheck (HPR2)               | $-0.31$ ($-0.35$, $-0.27$) | $0.86$ ($0.80$, $0.91$) |
| Febrile with SD Bioline (HPR2/pan-pLDH)     | $-0.37$ ($-0.47$, $-0.27$) | $0.96$ ($0.85$, $1.06$) |
| Febrile with SD Bioline (HPR2/Pv-pLDH)      | $-0.32$ ($-0.43$, $-0.20$) | $0.91$ ($0.75$, $1.09$) |
| Febrile with SD Bioline (HPR2)              | $-0.49$ ($-0.55$, $-0.44$) | $0.81$ ($0.69$, $0.95$) |
| Non-febrile with CareStart (HPR2/pan-pLDH)  | $0.30$ ($0.08$, $0.51$) | $1.30$ ($1.15$, $1.45$) |
| Non-febrile with First Response (HPR2/pan-pLDH) | $0.02$ ($-0.04$, $0.08$) | $0.89$ ($0.79$, $1.00$) |
| Non-febrile with First Response (HPR2)      | $-0.42$ ($-0.53$, $-0.31$) | $0.93$ ($0.85$, $1.03$) |
| Non-febrile with Paracheck (HPR2)           | $-0.09$ ($-0.12$, $-0.07$) | $0.93$ ($0.89$, $0.97$) |
| Non-febrile with SD Bioline (HPR2/pan-pLDH) | $-0.21$ ($-0.36$, $-0.07$) | $0.98$ ($0.87$, $1.07$) |
| Non-febrile with SD Bioline (HPR2/Pv-pLDH)  | $-0.12$ ($-0.19$, $-0.05$) | $0.96$ ($0.87$, $1.07$) |
| Non-febrile with SD Bioline (HPR2)          | $-0.53$ ($-0.58$, $-0.49$) | $0.65$ ($0.56$, $0.73$) |

the diagnosis and treatment strategies of proposed mass screen and treat campaigns [27]. In the absence of further data, some insight into the epidemiological processes behind the role of febrile status in RDT positivity rates may be gained from in silico experiments with mechanistic transmission codes if RDT measurement can be modelled immunologically, rather than by proxy through asexual density. Similar caveats apply to the interpretation of the results for the role of RDT brand in shaping the observed relationship.

The model incorporates random sampling noise for both the RDT and microscopy-derived measurements and the systematic noise of the RDT-derived measurements is addressed by exploring the factors that may influence the relationship. However, the systematic noise of the microscopy-derived measurements have not been explored here. There may be factors that are cause systematic noise to the relationship such as the condition of the microscope, microscopist’s training and judgement [11]. The data used here are from a consistent resource that uses a strict microscopy protocol in national facilities [11] and, therefore, these factors are likely to be minimal. Caution should however be applied when applying the presented regression function to microscopy-derived prevalence data from inconsistent sources with large variation in their diagnosing protocol.

There has been reports in some regions, mainly in South America, of $Pf$ with absent expression of HRP2 affecting RDT performance [28]. The occurrence of these reports have been marginal in sub-Saharan Africa [29, 30] and, therefore, unlikely to affect the analysis presented here, however caution should be applied when extended this to other geographic regions.

Previous evaluations of RDT diagnoses in field settings at specific sites (covering a limited range of transmission conditions) have identified a strong dependence of RDT specificity on age, such that overdiagnosis is most common amongst young children and much less common
amongst adults [31]. The results presented here are based on the DHS Programme data for children only; hence, the fitted relationships cannot be certified for conversion of all age prevalence survey data.

Conclusions

The research conducted in this paper offers a robust, data-driven approach for converting RDT-derived measurements of PfPR estimates into the more traditional microscopy-based measurements. The predictive accuracy of the conversion approach was high (correlation coefficient >0.9) for the generic, non-stratified model. The conversion technique developed here was a necessary precursor to the latest round of PfPR mapping in Africa by MAP [32] as it provides a means of including several national-level surveys for which only RDT data were collected. This technique is likely to become increasingly important in forthcoming years due to the increased usage of RDTs in P. falciparum-endemic countries.

Abbreviations

PfPR: Plasmodium falciparum parasite rate; RDT: Rapid diagnostic test; PCR: Polymerase chain reaction; MAP: Malaria Atlas Project; WHO: World Health Organization; DHS: Demographic and Health Surveys; ADMINI: Administrative zone; HRP2: Histidine-rich protein 2, pLDH: Plasmodium lactate dehydrogenase; ACT: Artemisinin-based combination therapy; PRMIC: Microscopy-derived Plasmodium falciparum parasite rate; PfPRMC: RDT-derived Plasmodium falciparum parasite rate; AIC: Akaike information criterion.

Authors’ contributions

BM developed the design of the study, acquired and assembled the data, reviewed contextual literature, carried out the analysis, interpreted results and drafted the manuscript. EC developed the regression model, assisted in the interpretation of the results and drafting of the manuscript. UD assisted in acquisition and assembly of the data, reviewing contextual literature, and drafting the manuscript. DJW assisted in the interpretation of results and the drafting of the manuscript. DB revised the manuscript. SB revised the manuscript. PWG conceived the idea of the study, developed the design of the study, drafted the manuscript. EC developed the regression model, assisted in reviewing contextual literature, carried out the analysis, interpreted results and drafted the manuscript. DB revised the manuscript. SB revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements

PWG is a Medical Research Council Career Development Fellow (#K00669X) and receives support from the Bill and Melinda Gates Foundation. PWG is a Medical Research Council Career Development Fellow (#K00669X) which also supports BM, EC, UD, DJW, SB, and DB. The authors declare that they have no competing interests.

Received: 23 July 2015   Accepted: 3 November 2015
Published online: 17 November 2015

References

1. Getting PW, Patil AP, Smith DL, Guerra CA, Elyazar IRFF, Johnston GL, Tatem AJ, Hay SI. A new world malaria map. Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.
2. Getting PW, Elyazar IRF, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map. Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6:e1814.
3. Noor AM, Kinyoki DK, Mundia CW, Kabaria CW, Mutua JW, Alegana VA, et al. The changing risk of Plasmodium falciparum malaria infection in Africa: 2000–2010: a spatial and temporal analysis of transmission intensity. Lancet. 2014;383:1739–47.
4. WHO: World Malaria Report. Geneva: World Health Organization; 2014.
5. Hay SI, Guerra CA, Gething PW, Patil AP, Tatem AJ, Noor AM, et al. A world malaria map. Plasmodium falciparum endemicity in 2007. PLoS Med. 2009;6:e100048.
6. Murray CJL, Ortblad KE, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:1055–70.
7. Liu L, Johnson HL, Counseller S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151–61.
8. Smith DL, Guerra CA, Snow RW, Hay SI. Standardizing estimates of the Plasmodium falciparum parasite rate. Malar J. 2007;6:131.
9. Oliver IC, Bousema T, Griffen JT, Quédraogo AL, Ghani AC, Drakeley CJ. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun. 2012;3:1237.
10. Abba K, Deeks JJ, Olliaro PL, Naing C-M, Jackson SM, Tawormong Y, et al. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. Cochrane Database Syst Rev. 2011;CD008122.
11. Wong-Aranisal C, Barcus MJ, Muth S, Sutamihardja A, Wiensdorfer WH. A review of malaria diagnostic tools: microscopy and rapid diagnostic test (RDT). Am J Epidemiol. 2007;7(7(Suppl)):119–27.
12. Kilian AHD, Metzger W, Mutschelknauss EJ, Kabagambe G, Landi P, Korte R, et al. Reliability of malaria microscopy in epidemiological studies: results of quality control. Trop Med Int Heal. 2000;5:3–8.
13. WHO: Good practices for selecting and procuring rapid diagnostic tests for malaria. Geneva: World Health Organization; 2012.
14. WHO. Malaria rapid diagnostic test performance: summary results of WHO product testing of malaria RDTs: round 1–5 (2008–2013). Geneva: World Health Organization, 2014.
15. Chioldini PL, Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J, et al. The heat stability of Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid diagnostic tests. Trans R Soc Trop Med Hyg. 2007;101:331–7.
16. Swarthout TD, Counihan H, Senga RKK, van den Broek I. Paracheck-Pf accuracy and recently treated Plasmodium falciparum infections: is there a risk of over-diagnosis? Malar J. 2007;6:58.
17. Mayxay M, Pukrittayakamee S, Chotivanich K, Looareesuwan S, White NJ. Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Trans R Soc Trop Med Hyg. 2001;95:179–82.
18. USAID. Demographic and Health Surveys. http://www.dhsprogram.com. Accessed 15 July 2015.
19. Richardson S, Leblond L, Jaussen I, Green PJ. Mixture models in measurement error problems, with reference to epidemiological studies. J R Stat Soc Ser A. 2002;165:549–66.
20. Escobar MD, West M. Bayesian density estimation and inference using mixtures. J Am Stat Assoc. 1995;90:577–88.
21. Albert JH, Chib S. Bayesian analysis of binary and polychotomous response data. J Am Stat Assoc. 1993;88:669–79.
22. Jara A, Hanson TE, Quintana FA, Müller P, Rosner GL. DIPpackage: Bayesian semi- and nonparametric modeling in R. J Stat Softw. 2011;40:1–30.
23. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19:716–23.
24. Iqbal J, Siddique A, Jameel M, Hira PR. Persistent histidine-rich protein 2, parasite lactate dehydrogenase, and panmalarial antigen reactivity after clearance of Plasmodium falciparum monoinfection. J Clin Microbiol. 2004;42:4237–41.
25. Abeku TA, Kristan M, Jones C, Beard J, Mueller DH, Okia M, et al. Determinants of the accuracy of rapid diagnostic tests in malaria case management: evidence from low and moderate transmission settings in the East African highlands. Malar J. 2008;7:202.
26. Ishengoma DS, Francis F, Mmbando BP, Lusingu JPA, Magistrado P, Alfandigis M, et al. Accuracy of malaria rapid diagnostic tests in community studies and their impact on treatment of malaria in an area with declining malaria burden in north-eastern Tanzania. Malar J. 2011;10:176.
27. Crowell V, Briet OJ, Hardy D, Chitsini N, Maire N, Di Pasquale A, et al. Modelling the cost-effectiveness of mass screening and treatment for reducing Plasmodium falciparum malaria burden. Malar J. 2013;12:4.
28. Cheng Q, Gatton ML, Barnwell J, Chiodini P, McCarthy J, Bell D, et al. *Plasmodium falciparum* parasites lacking histidine-rich protein 2 and 3: a review and recommendations for accurate reporting. *Malar J*. 2014;13:283.

29. Wurtz N, Fall B, Bui K, Pascual A, Fall M, Camara C, et al. Pfhrp2 and pfhrp3 polymorphisms in *Plasmodium falciparum* isolates from Dakar, Senegal: impact on rapid malaria diagnostic tests. *Malar J*. 2013;12:34.

30. Koita OA, Doumbo OK, Ouattara A, Tall LK, Konare A, Diakite M, et al. False-negative rapid diagnostic tests for malaria and deletion of the histidine-rich repeat region of the hrp2 gene. *Am J Trop Med Hyg*. 2012;86:194–8.

31. Laurent A, Schellenberg J, Shirima K, Ketende SC, Alonso PL, Mshinda H, et al. Performance of HRP-2 based rapid diagnostic test for malaria and itsvariation with age in an area of intense malaria transmission in southern Tanzania. *Malar J*. 2010;9:294.

32. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on *Plasmodium falciparum* in Africa between 2000 and 2015. *Nature*. 2015;526:207–11.